For NASH rats, YCHT demonstrated the ability to decrease not only hepatic triglyceride (TG) and FFA contents, but also the serum tumor necrosis factor-α (TNF-α) levels.11 Here, TNF is linked to metabolic dysfunction-associated steatohepatitis.